Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- JMA President Yokokura Heads WMA
October 17, 2017
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- Taskforce Discussing Info-Sharing Between Drug Makers in Non-Competitive Fields: JPMA R&D Head
October 12, 2017
- Generic Use Rate at 67.8% in April-June: JGA
September 29, 2017
- Biologics Training Center to Start Human Resources Development in Biologics Field Next April
September 20, 2017
- Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
- Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
- Plasma Fraction Products Should Remain in List of Essential Drugs: Blood Products Association Exec
September 11, 2017
- Introduce Permanent Price Maintenance Scheme, Don’t Rush on CEA Debate: UA Zensen
September 7, 2017
- JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
- LINK-J Expanding Free Consultation Service for Academic Researchers
August 31, 2017
- Cancer Advocate Warns of Lack of Patient Involvement in CEA Debates
August 30, 2017
- Impact of Drug Price Revisions on Company Management Unclear: JMA Think Tank
August 22, 2017
- JPWA Member Firms Suffer Record 3.5% Sales Fall on Drop-Off in Demand for Hepatitis C Meds
August 16, 2017
- Science Council of Japan Calls for Public-Private Partnerships to Spur Development of Psychiatric Disease Treatments
August 9, 2017
- New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
- EFPIA Japan to Provide 1 Million Yen to Support Patients’ Organizations
July 5, 2017
- Generic Use Rate at 65.5% in FY2016: JGA
June 30, 2017
- JMA Announces Endorsement for Chuikyo Rep Replacements
June 26, 2017
- FPMAJ Weighs Refined Version of “Similar Treatment Comparison” Pricing Method
June 20, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…